Drug Profile


Alternative Names: AM-94; RV3-BB

Latest Information Update: 04 Oct 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Murdoch Childrens Research Institute; Zenyth Therapeutics
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Rotavirus infections

Most Recent Events

  • 06 Jul 1999 SmithKline Beecham has decided not to exercise its option to license AM94 from Amrad, which has prompted the latter company to discontinue development of the vaccine
  • 06 Jul 1999 Discontinued-II for Rotavirus infections in Australia (PO)
  • 03 Oct 1997 Phase-II clinical trials for Rotavirus infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top